Hikma now expects 20% sales growth; Mylan to pay $250K fine in EpiPen ad case;

@FiercePharma: Best-read story this morning: Top 10 Drug Patent Losses for 2014. More | Follow @FiercePharma

@CarlyHFierce:  EU watchdogs demand info on AstraZeneca's disputed Brilinta trial. More | Follow @CarlyHFierce

> Jordan-based Hikma Pharmceuticals raised its sales forecast to reflect revenue growth of 20% and hiked its generics expectations on soaring sales of its antibiotic doxycycline. Report

> A Mylan ($MYL) subsidiary agreed to pay $250,000 to the state of Oregon and submit future TV commercials for review after allegations that its EpiPen advertising was misleading. Report

> The board of South Africa's Adcock Ingram continues to back a buyout bid from Chile's CFR Pharmaceuticals despite opposition from its biggest shareholder. Report

> India's drug regulator asked Sun Pharmaceuticals to halt clinical research at a Mumbai laboratory, saying the facility had not been approved. Report

> Polio may return to Europe as regional conflicts interfere with eradication efforts; the disease returned to war-torn Syria last month after a 14-year absence. Report

Medical Device News

@FierceMedDev: ICYMI: OrthoSensor links with Zimmer to sell knee replacement-balancing tech. Story | Follow @FierceMedDev

@MarkHFierce: Foundation Medicine's first quarterly earnings as a public company reflect impressive growth. Article | Follow @MarkHFierce

@MichaelGFierce: From FierceDrugDelivery this week: Novo Nordisk wins FDA approval for two automated-dose insulin pens. More | Follow @MichaelGFierce

> Chinese investors pursue groundbreaking med tech from Canada's MDI. News

> A pharma-free Covidien achieves moderate medical device growth. More

> Sequestration takes its toll on FDA user fees paid by industry. Item

Biotech News

@FierceBiotech: Teva fills CFO position as Desheh steps up to CEO, plus more of this week's career moves in biopharma. News | Follow @FierceBiotech

@JohnCFierce: FDA bottom line: unless there's a fantastic benefit, don't approve Lemtrada. Sanofi shares slip. | Follow @JohnCFierce

@DamianFierce: Updated Ariad job-cut story: EMA committee says Iclusig OK for now; stronger label on the way. More | Follow @DamianFierce

@EmilyMFierce: ICYMI: Report proposes revamping Alzheimer's R&D. Story | Follow @EmilyMFierce

> J&J innovation team sets up international collaboration to discover Alzheimer's drugs. Story

> Bristol-Myers axing up to 75 R&D staffers, halts discovery work in three fields. Article

> Sangart goes MIA after burning through $260M-plus on R&D. News

> FDA casts 'fatal' doubts on Sanofi's long-stalled MS drug Lemtrada. More

And Finally... The Obama administration is issuing rules defining equal treatment insurance coverage of mental illness and addiction. Report (sub. req.)